Therapeutic blocking antibodies against TNF-like cytokine 1A (TL1A) are emerging as one of the most compelling targets in inflammatory bowel disease (IBD). Preliminary phase 2 studies using TL1A-blocking antibodies have demonstrated some of the highest respons... ...

请注册登录后继续浏览